At a glance
ClinicalIndex Comparison Record- ✓Undergoing radiofrequency catheter ablation for scar VT from ischemic or non-ischemic cardiomyopathy
- ✕History of cerebral vascular accident or transient ischemic attack within 3 months
- ✕Cardiac or neurosurgery within 3 months of the ablation procedure
- ✕Any active bleeding
- ✕Severe hypersensitivity reaction to ELIQUIS
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
SafeTy and Efficacy of Direct Oral Anticoagulant Versus Aspirin for Reduction Of RisK of CErebrovascular Events in Patients Undergoing Ventricular Tachycardia Ablation (STROKE-VT)
In Brief
A Phase 4 clinical trial evaluating DOAC and Aspirin for Ventricular Tachycardia and 2 related conditions. Completed, enrolled 246 participants across 5 sites in 2 countries.
Detailed Summary
The purpose of this study is to learn if taking a drug called direct oral anticoagulant after an ablation procedure keeps blood clots from forming and lowers the chance of having a stroke in patients with ventricular tachycardia or arrhythmia (VT).
Study Details
Timeline
Interventions
DOAC is a blood thinning drug, also called direct oral anticoagulant. These group of drugs are approved by the U.S. Food and Drug Administration (FDA) for the treatment of stroke prophylaxis in atrial fibrillation and deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.
Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.